Cannabis consumption and development of psychosis: State of the art

Actas Espanolas de Psiquiatria

Volumn 35, Issue 3, 2007, Pages 182-189

  Roncero, C ^a,b   Collazos, F ^a   Valero, S ^a   Casas, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cannabis; Dependence; Psychosis; Vulnerability

Indexed keywords

ADOLESCENT; ADULT; CANNABIS ADDICTION; DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; MALE; PREVALENCE; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW; RISK FACTOR;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MARIJUANA ABUSE; PREVALENCE; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 34547359775     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Plan Nacional sobre Drogas. Informe no. 6, November (2003), available in www.msc.es/pnd
2. Fernández Corcuera P, Tiffon L, Sole J, San L. Dependencia de cannabis: implicaciones clínicas. A propósito de un caso. Actas Esp Psiquiatr 2003;31:299-301.
3. Arendt M, Munk-Jorgensen P. Heavy cannabis users seeking treatment-prevalence of psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol 2004;39:97-105.
4. Hall W, Swift W. The THC content of cannabis in Australia: evidence and implications. Aust N Z J Public Health 2000;24:503-8.
5. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004;291:2114-21.
6. Drugnet Europe (Boletín de Noticias del Observatorio Europeo de las Drogas y Toxicomanias): ¿gana potencia el cannabis? Informe julio-septiembre de 2004. Available in: www.emcdda.eu.int.
7. Plan Nacional sobre Drogas. Informe no. 5, julio (2002), available in www.msc.es/pnd.
8. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558-72.
9. Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr Res 2003 1;59:77-84.
10. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999;249:45-9.
11. Linszen DH, Dingemans PM, Nugter MA, Van der Does AJ, Scholte WF, Lenior MA. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull 1997;23:119-30.
12. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-6.
13. Martínez-Arévalo MJ, Calcedo-Ordónez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994;164:679-81.
14. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110-7.
15. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003;60:929-37.
16. Fergusson DM, Norwood LI, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003;33:15-21.
17. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99:1333-41.
18. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325(7374):1212-3.
19. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 2002;114:949-55.
20. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987;26;2:1483-6.
21. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 23;325:1183-8.
22. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 15;156:319-27.
23. Phillips U, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an «ultra» high-risk group. Aust N Z J Psychiatry 2002;36:800-6.
24. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003;20;71:37-48.
25. Boydell J, van Os J, Lambri M, Castle D, Allardyce J, McCreadie RG, et al. Incidence of schizophrenia in south-east London between 1965 and 1997. Br J Psychiatry 2003;182:45-9.
26. Hill Ab. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
27. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11-4.
28. Hall W. The psychotogenic effects of cannabis use: challenges in reducing residual uncertainties and communicating the risks. Addiction 2004;99:511-2.
29. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003;33:23-32.
30. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;27:276:2048-50.
31. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001;103:9-15.